1
|
Tielemans E, Rautenbach C, Khumalo Z, Beugnet F. Efficacy of a topical combination of esafoxolaner, eprinomectin and praziquantel against Amblyomma maculatum infestations in cats. Parasite 2024; 31:44. [PMID: 39109981 PMCID: PMC11305115 DOI: 10.1051/parasite/2024044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2024] [Accepted: 07/10/2024] [Indexed: 08/10/2024] Open
Abstract
Amblyomma maculatum, the Gulf Coast tick, infests a wide range of vertebrate species including livestock, dogs, cats, and humans. It is a species of significant veterinary and public health importance, especially as a vector of diseases, for instance American canine hepatozoonosis or tidewater spotted fever. An experimental study was conducted to evaluate the efficacy of NexGard® Combo, a topical endectoparasiticide product for cats combining eprinomectin, praziquantel and esafoxolaner, against induced infestations of A. maculatum in cats. This Good Clinical Practice (GCP) study used a randomized, negative controlled, masked design. Ten cats were allocated to an untreated group and ten to a treated group, dosed once on Day 0 at the minimum label dose. On Days -2, 7, 14, 21, 28, 35, and 42, cats were infested with ~50 unfed adult A. maculatum. On Days 3, 10, 17, 24, 31, 38, and 45, i.e., 72 h after treatment and subsequent infestations, ticks were removed, counted and the numbers of live attached tick in each group were used for efficacy calculations. At each time-point, all untreated cats were adequately infested, demonstrating a vigorous tick population and an adequate study model. The curative efficacy after a single application against existing tick infestation, 72 h after treatment, was 98.7%. The preventive efficacy, 72 h after weekly infestations, over the following five weeks ranged from 93.8% to 99.4%.
Collapse
Affiliation(s)
- Eric Tielemans
- Boehringer Ingelheim Animal Health 29 avenue Tony Garnier 69007 Lyon France
| | - Carin Rautenbach
- Clinvet International (Pty) Ltd. P.O. Box 11186 Universitas, Bloemfontein 9321 Republic of South Africa
| | - Zamantungwa Khumalo
- Clinvet International (Pty) Ltd. P.O. Box 11186 Universitas, Bloemfontein 9321 Republic of South Africa
| | - Frederic Beugnet
- Boehringer Ingelheim Animal Health 29 avenue Tony Garnier 69007 Lyon France
| |
Collapse
|
2
|
Raulf MK, Raue K, Rohdich N, Zschiesche E, Raue J, Merhof K, Volk HA, Schnyder M, Morelli S, Traversa D, Roepke RKA, Strube C. Efficacy of Bravecto ® Plus spot-on solution for cats (280 mg/ml fluralaner and 14 mg/ml moxidectin) in the prevention of feline Aelurostrongylus abstrusus infection evaluated in a multi-diagnostic approach. Parasit Vectors 2024; 17:193. [PMID: 38658960 PMCID: PMC11044604 DOI: 10.1186/s13071-024-06270-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Accepted: 04/03/2024] [Indexed: 04/26/2024] Open
Abstract
BACKGROUND Aelurostrongylus abstrusus is one of the most important respiratory nematodes of felines. Infections may lead to respiratory clinical signs with varying severity or even death, emphasizing the need for preventive treatment of cats with outdoor access to circumvent patent infections. METHODS Therefore, the preventive efficacy of a spot-on formulation of 280 mg/ml fluralaner and 14 mg/ml moxidectin (Bravecto® Plus spot-on solution for cats, MSD) against A. abstrusus was evaluated in a negative controlled, randomized and partially blinded efficacy study with 28 purpose-bred cats in a non-terminal design. In three different treatment regimes, the minimum recommended dose of 40 mg fluralaner and 2.0 mg moxidectin/kg bodyweight (BW) was administered once at 12, 8 or 4 weeks (study group G1, G2 and G3, respectively) prior to experimental infection with 300 third-stage A. abstrusus larvae, while G4 served as placebo-treated control. RESULTS From 30 to 46 days post infection (dpi; SD 114 to 130), faeces were sampled to monitor first-stage larvae (L1) excretion for efficacy determination. Secondary efficacy criteria, including respiratory parameters, serological antibody levels and computed tomography (CT) findings, were assessed once before enrolment (SD -7 to -1) and before infection (SD 75 to 83). After infection, CT evaluation was performed once at 47-50 dpi (SD 131 to 134), and respiratory parameters and antibody levels were regularly assessed twice or once a week, respectively (1 up to 78 dpi, SD 85 up to 162). All animals in the control group excreted L1 by 33-37 dpi and remained positive throughout the study period from 41 to 46 dpi (SD 125 to 130). In the treatment groups, only one animal each of G1 and G2 excreted L1 at two consecutive days, and four cats of G1, two of G2 and three of G3 were positive on single occasions. While the geometric mean (GM) of the maximum number of excreted L1 per 5 g of faeces was 7380.89 in the control group (G4), GMs were significantly lower in the treatment groups with 1.63 in G1, 1.37 in G2 and 0.79 in G3. Thus, based on GMs, the reduction in excreted L1 exceeded 99.9% in all three treatment groups. Based on CT severity scores, all lungs of the animals of the control group showed severe pulmonary changes post infection, whereas lungs of the cats of the treatment groups were either unaltered (4 animals), mildly (11 animals), or moderately altered (5 animals). Moreover, seroconversion was observed in all cats of the control group, but not in those of the treatment groups. CONCLUSIONS The combination of diagnostic methods used in this non-terminal study yielded coherent and reliable results. A single administration of Bravecto® Plus spot-on solution for cats was well tolerated and effective in the prevention of aelurostrongylosis for at least 12 weeks.
Collapse
Affiliation(s)
- Marie-Kristin Raulf
- Institute for Parasitology, Centre for Infection Medicine, University of Veterinary Medicine Hannover, Buenteweg 17, 30559, Hanover, Germany
| | - Katharina Raue
- Institute for Parasitology, Centre for Infection Medicine, University of Veterinary Medicine Hannover, Buenteweg 17, 30559, Hanover, Germany
| | - Nadja Rohdich
- MSD Animal Health Innovation GmbH, Schwabenheim, Germany
| | - Eva Zschiesche
- MSD Animal Health Innovation GmbH, Schwabenheim, Germany
| | - Jonathan Raue
- Department for Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, 30559, Hannover, Germany
| | - Kristina Merhof
- Department for Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, 30559, Hannover, Germany
| | - Holger A Volk
- Department for Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, 30559, Hannover, Germany
| | - Manuela Schnyder
- Institute of Parasitology, Vetsuisse Faculty, University of Zurich, 8057, Zurich, Switzerland
| | - Simone Morelli
- Department of Veterinary Medicine, University of Teramo, Teramo, Italy
| | - Donato Traversa
- Department of Veterinary Medicine, University of Teramo, Teramo, Italy
| | | | - Christina Strube
- Institute for Parasitology, Centre for Infection Medicine, University of Veterinary Medicine Hannover, Buenteweg 17, 30559, Hanover, Germany.
| |
Collapse
|
3
|
Di Cesare A, Zanet S, Traversa D, Colombo M, Tielemans E, Beugnet F, Ferroglio E. Efficacy of a combination of esafoxolaner, eprinomectin and praziquantel (NexGard ® Combo) against Thelazia callipaeda in naturally infected cats. Parasite 2024; 31:10. [PMID: 38415717 PMCID: PMC10901074 DOI: 10.1051/parasite/2024008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2023] [Accepted: 01/22/2024] [Indexed: 02/29/2024] Open
Abstract
This clinical study assessed the efficacy of a topical combination of esafoxolaner, eprinomectin and praziquantel (NexGard® Combo) in treating cats naturally infected with the eyeworm Thelazia callipaeda (Nematoda, Thelaziidae). On Study Day (SD) 0, sixteen client-owned cats with eyeworm infection were allocated to an untreated control group (G1, 8 cats) or to a NexGard® Combo treated group (G2, 8 cats) and subjected to ocular examination. Cats in G2 received the treatment as per label recommendations. On SD 7 and 14 (±1), cats were examined for the presence of eyeworms and clinical signs. On SD 14, eyeworms were collected and counted. On SD 7 and 14, all cats in G1 were still infected with eyeworms, while G2 cats were free from eyeworms on SD 7 and 14, demonstrating 100% efficacy (p < 0.0001). All collected eyeworms were morphologically and molecularly confirmed to be T. callipaeda. On SD 0, fifteen out of the sixteen cats (7 in G1 and 8 in G2) displayed inflammatory ocular signs. On SD 7, all eight untreated cats and seven treated cats displayed inflammatory ocular signs. On SD 14, five out of eight G2 treated cats had recovered, while the eight untreated cats still displayed inflammatory ocular signs. The treatment significantly reduced lacrimation and conjunctivitis (p = 0.0001). No adverse reactions occurred. This clinical study provides evidence that NexGard® Combo is highly safe and effective for the treatment of T. callipaeda infection in cats under field conditions.
Collapse
Affiliation(s)
- Angela Di Cesare
- Department of Veterinary Medicine, University of Teramo, Località Piano d'Accio, 64100 Teramo, Italy
| | - Stefania Zanet
- Department of Veterinary Sciences, University of Turin, Largo Paolo Braccini 2, 10095 Grugliasco, Turin, Italy
| | - Donato Traversa
- Department of Veterinary Medicine, University of Teramo, Località Piano d'Accio, 64100 Teramo, Italy
| | - Mariasole Colombo
- Department of Veterinary Medicine, University of Teramo, Località Piano d'Accio, 64100 Teramo, Italy
| | - Eric Tielemans
- Boehringer Ingelheim Animal Health, 29 Avenue Tony Garnier, 69007 Lyon, France
| | - Frederic Beugnet
- Boehringer Ingelheim Animal Health, 29 Avenue Tony Garnier, 69007 Lyon, France
| | - Ezio Ferroglio
- Department of Veterinary Sciences, University of Turin, Largo Paolo Braccini 2, 10095 Grugliasco, Turin, Italy
| |
Collapse
|
4
|
Mihalca AD, Deak G, Panait LC, Rabei Ș, Beugnet F. Efficacy of a topical formulation containing esafoxolaner, eprinomectin and praziquantel (NexGard Combo ®) against natural infestations with the cat louse, Felicola subrostratus under field conditions. Parasite 2022; 29:62. [PMID: 36562429 PMCID: PMC9879157 DOI: 10.1051/parasite/2022062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2022] [Accepted: 12/04/2022] [Indexed: 12/24/2022] Open
Abstract
Felicola subrostratus is the only species of louse affecting domestic cats. Although it is considered a rare ectoparasite of pet cats, it occurs mainly in stray or shelter animals and is sometimes associated with intense pruritus and secondary bacterial infections. The aim of the present study was to evaluate the efficacy of a single dose of the topical formulation of esafoxolaner, eprinomectin and praziquantel (NexGard Combo®, Boehringer Ingelheim) in cats for the treatment of naturally acquired chewing lice infestation in a multi-site, positive-control, blinded clinical field study. Thirty-one domestic cats presenting natural F. subrostratus infestation were included in the study. The animals had not been treated with any ectoparasiticide within the previous 60 days. After inclusion, each cat was randomly assigned to one of the two groups: group 1, 14 cats treated with NexGard Combo® or group 2, 17 cats treated with Frontline Combo®. A clinical evaluation was performed at days 0 (inclusion), 14 and 30 and consisted in scoring the skin lesions and symptoms and scoring the presence of lice. On day 30, all cats from both groups scored 0 for the presence of live lice and no dead lice were found, demonstrating 100% efficacy. The clinical scores significantly improved from day 0 to day 30 in both groups. During the 30 days of surveillance, no reinfestations due to the hatching of eggs were observed and none of the cats had any adverse reactions. Esafoxolaner demonstrated high efficacy for the treatment of F. subrostratus infestation.
Collapse
Affiliation(s)
- Andrei Daniel Mihalca
- Department of Parasitology and Parasitic Diseases, University of Agricultural Sciences and Veterinary Medicine of Cluj-Napoca Calea Mănăștur 3–5 400372 Cluj-Napoca Romania,Parasitology Consultancy Group SRL Strada Principală 145B 407056 Corușu Romania
| | - Georgiana Deak
- Department of Parasitology and Parasitic Diseases, University of Agricultural Sciences and Veterinary Medicine of Cluj-Napoca Calea Mănăștur 3–5 400372 Cluj-Napoca Romania
| | - Luciana Cătălina Panait
- Department of Parasitology and Parasitic Diseases, University of Agricultural Sciences and Veterinary Medicine of Cluj-Napoca Calea Mănăștur 3–5 400372 Cluj-Napoca Romania
| | - Ștefan Rabei
- Department of Parasitology and Parasitic Diseases, University of Agricultural Sciences and Veterinary Medicine of Cluj-Napoca Calea Mănăștur 3–5 400372 Cluj-Napoca Romania
| | - Frederic Beugnet
- Boehringer Ingelheim Animal Health Av Tony Garnier 69007 Lyon France
| |
Collapse
|
5
|
Cvejić D, Hellmann K, Petry G, Ringeisen H, Hamburg H, Farkas R, Blazejak K, Mencke N. Multicenter randomized, and blinded European field study evaluating the efficacy and safety of Felpreva®, a novel spot-on formulation containing emodepside, praziquantel and tigolaner, in treating cats naturally infested with fleas and/or ticks. CURRENT RESEARCH IN PARASITOLOGY & VECTOR-BORNE DISEASES 2022; 2:100099. [PMID: 35991085 PMCID: PMC9382417 DOI: 10.1016/j.crpvbd.2022.100099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 04/23/2022] [Accepted: 07/14/2022] [Indexed: 11/16/2022]
Abstract
The present field study evaluated the safety and 3-month preventive efficacy of a novel spot-on endectocide containing emodepside 2.04% w/v, praziquantel 8.14% w/v and tigolaner 9.79% w/v (Felpreva®, Vetoquinol) when administered at the intended commercial dose of 0.15 ml/kg body weight to privately owned cats infested by fleas (Ctenocephalides felis) and/or ticks (Ixodes ricinus, Ixodes hexagonus, Rhipicephalus spp.). The efficacy of Felpreva® to reduce the clinical signs associated with flea allergy dermatitis was also evaluated. A total of 326 cats, i.e. 120 and 206 infested by ticks and fleas respectively, from 16 different sites located in Hungary and Portugal were included on Day 0 and allocated in two Groups at a ratio of 2:1 (T1:T2). Cats of T1 were treated with Felpreva®, while cats of T2 were dosed with a commercial Control Product (Bravecto®, MSD Animal Health) licensed for the same indications. Of the 120 tick-infested cats, 79 and 41 were treated with Felpreva® and Bravecto® respectively, while of the 206 flea-infested cats, 139 were treated with Felpreva® and 67 with Bravecto®. Cats were physically examined on Days 7, 28, 56, 75 and 90; when present, fleas and ticks were counted and collected. Efficacy evaluation was based on the mean percent reduction of live parasite counts for each of five visits versus the pre-treatment count. Percent reductions of live flea and tick counts over all post-baseline periods were 99.74% (T1) versus 98.56% (T2) and 97.50% (T1) versus 98.65% (T2), respectively. Non-inferiority for the Felpreva® compared with the Bravecto® treated group was statistically demonstrated for both fleas and ticks. Three adverse events were observed and considered unlikely related to the treatment. These results show that the new topical combination product Felpreva® is safe and highly efficacious in treating flea and tick infections in cats for at least three months (90 days) with a single administration. In 16 cats that were identified with flea allergy dermatitis, the clinical signs of flea allergy dermatitis improved following treatment in both groups.
Collapse
Affiliation(s)
- Dejan Cvejić
- Klifovet GmbH, Geyerspergerstr. 27, 80689, München, Germany
| | - Klaus Hellmann
- Klifovet GmbH, Geyerspergerstr. 27, 80689, München, Germany
| | - Gabriele Petry
- Bayer Animal Health GmbH an Elanco Animal Health Company, Alfred Nobel Str. 50, 40789, Monheim, Germany
| | - Hannah Ringeisen
- Bayer Animal Health GmbH an Elanco Animal Health Company, Alfred Nobel Str. 50, 40789, Monheim, Germany
| | - Hannah Hamburg
- Bayer Animal Health GmbH an Elanco Animal Health Company, Alfred Nobel Str. 50, 40789, Monheim, Germany
| | - Róbert Farkas
- Department of Parasitology and Zoology, Faculty of Veterinary Medicine, Szent István University, István u. 2, Budapest, 1078, Hungary
| | - Katrin Blazejak
- Vetoquinol S.A., 37 rue de la Victoire, 75009, Paris, France
| | - Norbert Mencke
- Vetoquinol S.A., 37 rue de la Victoire, 75009, Paris, France
| |
Collapse
|
6
|
Lavy E, Kirmayer D, Nudelman Z, Orenshtein-Vilensky L, Rowan TG, Shenderovich-Gefter J, Friedman M. Aspects in controlled drug delivery for topical applications in veterinary medicine. Vet Anim Sci 2022; 15:100235. [PMID: 35265770 PMCID: PMC8899706 DOI: 10.1016/j.vas.2022.100235] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2021] [Revised: 01/28/2022] [Accepted: 01/28/2022] [Indexed: 11/16/2022] Open
Abstract
The controlled release of drugs is an appealing area of research as it provides numerous benefits in veterinary and human medicine. In this paper we attempt to analyze certain aspects related to topical drug delivery systems, their successes and failures, and their place in veterinary medicine. Some emphasis is given to the pharmaceutical aspects of the delivery systems, where the material available made it possible. Purely topical devices, such as cattle ear tags and various collars, as well as some topically administered bioavailable delivery systems are discussed. Special attention is given to hitherto under-evaluated delivery systems, such as topical varnishes. A carefully selected bibliography aims to lead the reader easily to the facts, without providing overwhelming data of varying quality. We believe that the paper may be of interest to practicing veterinarians as well as to pharmaceutical scientists working or considering practice in the area.
Collapse
Affiliation(s)
- Eran Lavy
- The Robert H. Smith Faculty of Agriculture, Food and Environment, Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, P.O.B. 12, Rehovot 76100, Israel
| | - David Kirmayer
- Department of Pharmaceutics, Faculty of Medicine, The Institute for Drug Research, The Hebrew University of Jerusalem, P.O.B 12065, Jerusalem 91120, Israel
| | - Zakhar Nudelman
- The Robert H. Smith Faculty of Agriculture, Food and Environment, Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, P.O.B. 12, Rehovot 76100, Israel
| | | | | | - Julia Shenderovich-Gefter
- Department of Pharmaceutics, Faculty of Medicine, The Institute for Drug Research, The Hebrew University of Jerusalem, P.O.B 12065, Jerusalem 91120, Israel
- Israel Patent Authority, Ministry of Justice, Jerusalem, Israel
| | - Michael Friedman
- Department of Pharmaceutics, Faculty of Medicine, The Institute for Drug Research, The Hebrew University of Jerusalem, P.O.B 12065, Jerusalem 91120, Israel
| |
Collapse
|
7
|
Traversa D, Raue K, Ringeisen H, Blazejak K, Bisterfeld K, Di Cesare A, Colombo M, Böhm C, Strube C, Pollmeier M. Efficacy of a spot-on combination containing 10% w/v imidacloprid and 1% w/v moxidectin for the treatment of troglostrongylosis in experimentally infected cats. Parasit Vectors 2022; 15:66. [PMID: 35193656 PMCID: PMC8862244 DOI: 10.1186/s13071-022-05185-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Accepted: 01/28/2022] [Indexed: 12/29/2022] Open
Abstract
Background Parasitic bronchopneumonia in domestic cats in Europe, which can manifest with moderate to severe clinical signs, is frequently caused by Troglostrongylus brevior. Data on epizootiological and clinical relevance of cat troglostrongylosis have been published in the last decade but treatment options are still limited. Promising effectiveness data have been generated from clinical cases and field trials for a spot-on formulation containing 1% w/v moxidectin and 10% w/v imidacloprid (Advocate®, Elanco Animal Health). Therefore, two studies have been conducted to confirm under experimental conditions the efficacy of moxidectin 1% contained in Advocate® for the treatment of cat troglostrongylosis. Methods Sixteen and 20 cats experimentally infected with T. brevior were included in two separate studies, i.e., Study 1 and 2, respectively. Cats were infected with T. brevior third-stage larvae via gastric tube. In both studies cats were randomized to untreated (control, Group 1) and treatment (Group 2) groups. In Study 1 and Study 2, the two groups comprised eight and 10 cats each. Treated cats received Advocate® spot-on twice at a 4-week interval. The primary efficacy criterion was the number of viable adult T. brevior counted at necropsy. Throughout the trial, the fecal shedding of first-stage larvae (L1) was assessed in treated and untreated control cats. Results The experimental model was successful in both studies, as all cats started shedding T. brevior L1 within 25 days post-infection. At necropsy, T. brevior adults were found in 4/8 and 4/10 cats of the control groups in Study 1 and 2, respectively, while none of the treated cats harbored adult worms. The necropsy worm counts in controls did not meet relevant guideline requirements for adequacy of infection, with fewer than six infected cats in the control groups, thus limiting conclusions on treatment efficacy. The fact that 6/8 and 8/10 control cats in Study 1 and 2, respectively, shed L1 up to necropsy while larval shedding ceased in all treated animals after the first treatment provides supporting evidence on the level of efficacy. No remarkable adverse events were recorded in the two studies. Conclusion These results indicate that Advocate® spot-on is a safe and effective option for treating cats infected by T. brevior. Graphical Abstract ![]()
Collapse
Affiliation(s)
| | - Katharina Raue
- Institute for Parasitology, Centre for Infection Medicine, University of Veterinary Medicine Hannover, Hanover, Germany
| | - Hannah Ringeisen
- Elanco Animal Health, Bayer Animal Health GmbH, Monheim, Germany
| | - Katrin Blazejak
- Elanco Animal Health, Bayer Animal Health GmbH, Monheim, Germany
| | - Katrin Bisterfeld
- Institute for Parasitology, Centre for Infection Medicine, University of Veterinary Medicine Hannover, Hanover, Germany
| | | | | | - Claudia Böhm
- Elanco Animal Health, Bayer Animal Health GmbH, Monheim, Germany
| | - Christina Strube
- Institute for Parasitology, Centre for Infection Medicine, University of Veterinary Medicine Hannover, Hanover, Germany
| | | |
Collapse
|
8
|
Traversa D, Morelli S, Di Cesare A, Strube C, Raue K, Bisterfeld K, Boehm C, Pollmeier M, Ringeisen H, Blazejak K, Mencke N. Efficacy of two topical combinations containing emodepside plus praziquantel, and emodepside plus praziquantel plus tigolaner, for the treatment of troglostrongylosis in experimentally infected cats. CURRENT RESEARCH IN PARASITOLOGY & VECTOR-BORNE DISEASES 2022; 2:100097. [PMID: 35991087 PMCID: PMC9382431 DOI: 10.1016/j.crpvbd.2022.100097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 07/12/2022] [Accepted: 07/14/2022] [Indexed: 11/16/2022]
Affiliation(s)
- Donato Traversa
- Faculty of Veterinary Medicine, University of Teramo, Località Piano DʼAccio, 64100 Teramo (TE), Italy
| | - Simone Morelli
- Faculty of Veterinary Medicine, University of Teramo, Località Piano DʼAccio, 64100 Teramo (TE), Italy
| | - Angela Di Cesare
- Faculty of Veterinary Medicine, University of Teramo, Località Piano DʼAccio, 64100 Teramo (TE), Italy
| | - Christina Strube
- Institute for Parasitology, Centre for Infection Medicine, University of Veterinary Medicine Hannover, Buenteweg 17, Hannover, Germany
| | - Katharina Raue
- Institute for Parasitology, Centre for Infection Medicine, University of Veterinary Medicine Hannover, Buenteweg 17, Hannover, Germany
| | - Katrin Bisterfeld
- Institute for Parasitology, Centre for Infection Medicine, University of Veterinary Medicine Hannover, Buenteweg 17, Hannover, Germany
| | - Claudia Boehm
- Bayer Animal Health GmbH an Elanco Animal Health Company, Alfred Nobel Str. 50, 40789 Monheim, Germany
| | - Matthias Pollmeier
- Bayer Animal Health GmbH an Elanco Animal Health Company, Alfred Nobel Str. 50, 40789 Monheim, Germany
| | - Hannah Ringeisen
- Bayer Animal Health GmbH an Elanco Animal Health Company, Alfred Nobel Str. 50, 40789 Monheim, Germany
| | | | - Norbert Mencke
- Vetoquinol S.A., 37 rue de la Victoire, 75009 Paris, France
- Corresponding author.
| |
Collapse
|